Summary
Patent claims are construed by asking what the skilled person would understand the claim language to mean in the context of the specification. The description cannot impose a requirement that the claim language does not contain. Priority requires the claimed subject matter to be derivable directly and unambiguously from the priority document as a whole. A disclosure which merely makes a feature obvious does not disclose it for priority purposes. The 726 and 675 patents were not entitled to priority and were consequently invalid. The 726 claims were also obvious on their proper construction.
Factual background
Samsung alleged that Apple’s UMTS-compliant devices infringed European patents UK Nos 1,005,726 and 1,357,675. Apple denied infringement and counterclaimed for revocation. Samsung abandoned infringement of the 675 patent shortly before trial, but validity remained in issue.
The judgment concerned construction, priority, infringement, obviousness and proposed amendments. The central questions were whether the claims covered the alleged technology, whether their subject matter was directly and unambiguously disclosed in the Korean priority applications, and whether the claims would otherwise have been obvious.
Held
The court held that both patents were invalid because the relevant claims were not entitled to their claimed priority, and Samsung had accepted that intervening prior art then invalidated them. The 726 patent would also have been invalid for obviousness, although its claims would have been infringed by Apple’s UMTS-compliant devices if valid.
- Construction. Claims are construed purposively through the eyes of the skilled person. The specification assists in understanding the claim language but cannot replace or expand it. The 726 claims did not require an encoder capable of changing superframe size during an ongoing transmission. “QoS parameter” was used broadly to include anything capable of affecting user satisfaction, including actual data rate and channel conditions, but not service type itself.
- Priority. The court applied the substance-based test: read the priority document as a whole through the skilled person’s eyes, identify the claim subject matter, and ask whether it is directly and unambiguously derivable. The 726 priority document did not disclose the wider class of independent parameters claimed. The 675 priority document did not disclose filler bits; their use was only one of several obvious solutions to the non-integer case.
- Obviousness. Applying the structured approach in Pozzoli v BDMO [2007] EWCA Civ 588, claims 1 and 14 of 726 were obvious over Bömer and Valenti on the correct construction. The proposed sequential-allocation amendment to 675 would not have been obvious if priority had been established.
The conclusions were recorded at paragraph [201].
The court’s approach to earlier authorities
Available to signed-in members.
Key cases cited
13 authorities cited.
- Conor Medsystems Incorporated (Respondents) v Angiotech Pharmaceuticals Incorporated and others (Appellants) [2008] UKHL 49
- Synthon BV (Appellants) v. Smithkline Beecham plc (Respondents) (HTML version) [2005] UKHL 59
- Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2005] RPC 9
- Virgin Atlantic Airways Ltd v Premium Aircraft Interiors UK Ltd [2009] EWCA Civ 1062
- Pozzoli Spa v BDMO SA & Anor [2007] EWCA Civ 588
- Mayne Pharma PTY Ltd & Anor v Pharmacia Italia SPA [2005] EWCA Civ 137
- Unilin Beheer BV v Berry Floor NV & Ors [2004] EWCA Civ 1021
- Abbott Laboratories Ltd v Evysio Medical Devices ULC [2008] EWHC 800 (Pat)
- Generics (UK) Ltd v H Lundbeck A/S [2007] RPC 32
- Halliburton Energy Services Inc v Smith International (North Sea) Ltd [2005] EWHC 1623 (Pat)
- G02/98 Same Invention [2002] EPOR 167
- Medimmune Limited v Novartis Pharmaceuticals Limited
- Landgericht Mannheim decision dated 20 January 2012
Sign in to see how the court treated each authority. A free account is enough.
Cases citing this case
4 later cases · 3 positive · 1 caution
Most senior citing decisions:
- Unwired Planet International Ltd v Huawei Technologies Co Ltd & Ors [2017] EWCA Civ 266 applied
- Icescape Ltd v Ice-World International BV & Anor [2017] EWHC 42 (Pat) explained
- Actavis & Ors v Eli Lilly And Company [2016] EWHC 1955 (Pat) approved
- HTC Corporation v Gemalto SA [2013] EWHC 1876 (Pat)
Sign in for the full treatment table. A free account is enough.